Biomensio has run a small pre-clinical study in collaboration with Northern Finland Social and Health Care joint authority. Saliva samples taken from PCR positive patients were analysed using the Biomensio technology and compared to lateral flow tests.
Collaboration with health care professionals with a keen interest in testing new technologies is of paramount importance – the collaboration with authorities in Kainuu has been very constructive and uncomplicated, providing Biomensio the possibility to experiment with real life active samples. The preliminary results were very encouraging for the continued development of SARS-CoV-2 detection with Biomensio technology.
We have started a collaboration with the Division of Infectious Diseases and Tropical Medicine at Ludwig Maximilian University in Munich in order to evaluate and further develop the performance of SARS-CoV-2 testing based on our technology. Such collaboration with key opinion leaders and medical experts is essential for the further development of the Biomensio diagnostics technology and instrumentation meeting the end-user requirements. Currently a multiphase study comparing the Biomensio test results with PCR results, as well as lateral flow tests for SARS-CoV-2 detection is ongoing with promising results.
Advantages of the Biomensio technology for detection of infectious diseases are its simplicity, ease of use, as well as rapid and label-free detection. Microarray format of the Biomensio platform allows simultaneous detection of multiple pathogens and biomarkers. Results are displayed digitally thus alleviating need for visual interpretation of often ambiguous lateral flow results.